Analysis: US FDA faces mounting criticism over Alzheimer’s drug approval ...Egypt

EGYPT INDEPENDENT - News
Analysis: US FDA faces mounting criticism over Alzheimer’s drug approval
In approving the first new Alzheimer’s drug in nearly 20 years, the US Food and Drug Administration is taking its biggest risk yet with a strategy that allows new therapies onto the market without strong evidence that they work, regulatory and scientific experts say. The Biogen Inc (BIIB.O) drug, Aduhelm, was authorized based on evidence that it can reduce brain plaques, a likely contributor to Alzheimer’s, rather than proof that it slows progression of the lethal mind-wasting disease. The FDA has granted so-called “accelerated approval” in more than 250 instances since 1992, mainly for rare diseases or small patient populations that have had no effective treatments available to them. In the

Hence then, the article about analysis us fda faces mounting criticism over alzheimer s drug approval was published today ( ) and is available on EGYPT INDEPENDENT ( Egypt ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Analysis: US FDA faces mounting criticism over Alzheimer’s drug approval )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News